advanceCor GmbH
Biotech company independent development of innovative drugs + diagnostics for heart disease, cardiology
Biotech company independent development of innovative drugs + diagnostics for heart disease, cardiology
advanceCOR GmbH is a pioneering clinical drug development company founded in 2012, specializing in therapeutics and diagnostics for cardiovascular diseases. The company's products, including Revacept, COR-2, and COR-3, demonstrate innovative approaches to preventing platelet activation, interfering with foam cell formation, and accelerating plaque healing. With a focus on biotechnology, advanceCOR attained a significant milestone with a €6.00M Venture Round investment on 21 May 2018, garnering support from prominent investors such as Bayern Kapital, KfW, MIG AG, Occident, and HTGF | High-Tech Gruenderfonds. The company's extensive portfolio and strategic investments position advanceCOR as a key player in advancing solutions for heart and vascular health.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | €6.00M | 5 |
|
21 May 2018 |
No recent news or press coverage available for advanceCor GmbH.
We care about your data, and we'd love to use cookies make your experience better.
